blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3380468

EP3380468 - BIS-PYRIDAZINE COMPOUNDS AND THEIR USE IN TREATING CANCER [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  26.03.2021
Database last updated on 21.09.2024
FormerThe patent has been granted
Status updated on  17.04.2020
FormerGrant of patent is intended
Status updated on  17.03.2020
FormerRequest for examination was made
Status updated on  28.02.2020
FormerGrant of patent is intended
Status updated on  18.07.2019
FormerRequest for examination was made
Status updated on  31.08.2018
FormerThe international publication has been made
Status updated on  02.06.2017
Formerunknown
Status updated on  07.12.2016
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Cancer Research Technology Limited
2 Redman Place
London E20 1JQ / GB
[2020/33]
Former [2020/21]For all designated states
Astrazeneca AB
151 85 Södertälje / SE
For all designated states
Cancer Research Technology Ltd.
Angel Building
407 St. John Street
London EC1V 4AD / GB
Former [2018/40]For all designated states
Astrazeneca AB
151 85 Södertälje / SE
For all designated states
Cancer Research Technology Ltd.
Angel Building
407 St. John Street
London EC1V 4AD / GB
Inventor(s)01 / FINLAY, Maurice, Raymond, Verschoyle
AstraZeneca R&D Cambridge
Darwin Building Cambridge Science Park
Milton Road
Cambridge Cambridgeshire CB4 0FZ / GB
 [2018/40]
Representative(s)HGF
HGF Limited
1 City Walk
Leeds LS11 9DX / GB
[N/P]
Former [2020/21]HGF Limited
4th Floor
Merchant Exchange
17-19 Whitworth Street West
Manchester M1 5WG / GB
Former [2018/40]AstraZeneca
Milstein Building
Granta Park
Cambridge CB21 6GH / GB
Application number, filing date16801774.725.11.2016
[2018/40]
WO2016EP78899
Priority number, dateGB2015002095927.11.2015         Original published format: GB 201520959
[2018/40]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017089587
Date:01.06.2017
Language:EN
[2017/22]
Type: A1 Application with search report 
No.:EP3380468
Date:03.10.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 01.06.2017 takes the place of the publication of the European patent application.
[2018/40]
Type: B1 Patent specification 
No.:EP3380468
Date:20.05.2020
Language:EN
[2020/21]
Type: B8 Corrected title page of specification 
No.:EP3380468
Date:04.11.2020
[2020/45]
Search report(s)International search report - published on:EP01.06.2017
ClassificationIPC:C07D403/14, A61K31/501, A61P35/00
[2018/40]
CPC:
C07D403/14 (EP,KR,US); A61K31/501 (KR); A61P35/00 (EP,KR);
A61P43/00 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/40]
Extension statesBA27.06.2018
ME27.06.2018
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:BIS-PYRIDAZIN-VERBINDUNGEN UND DEREN VERWENDUNG IN DER BEHANDLUNG VON KREBS[2018/40]
English:BIS-PYRIDAZINE COMPOUNDS AND THEIR USE IN TREATING CANCER[2018/40]
French:COMPOSÉS DE BIS-PYRIDAZINE ET LEUR UTILISATION DANS LE TRAITEMENT DU CANCER[2018/40]
Entry into regional phase27.06.2018National basic fee paid 
27.06.2018Designation fee(s) paid 
27.06.2018Examination fee paid 
Examination procedure14.06.2018Amendment by applicant (claims and/or description)
14.06.2018Date on which the examining division has become responsible
27.06.2018Examination requested  [2018/40]
19.07.2019Communication of intention to grant the patent
16.01.2020Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time
25.02.2020Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
18.03.2020Communication of intention to grant the patent
09.04.2020Fee for grant paid
09.04.2020Fee for publishing/printing paid
09.04.2020Receipt of the translation of the claim(s)
Opposition(s)23.02.2021No opposition filed within time limit [2021/17]
Request for further processing for:The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
25.02.2020Request for further processing filed
25.02.2020Full payment received (date of receipt of payment)
Request granted
05.03.2020Decision despatched
Fees paidRenewal fee
30.11.2018Renewal fee patent year 03
25.11.2019Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU25.11.2016
AL20.05.2020
AT20.05.2020
CY20.05.2020
CZ20.05.2020
EE20.05.2020
HR20.05.2020
LT20.05.2020
LV20.05.2020
MC20.05.2020
MK20.05.2020
MT20.05.2020
PL20.05.2020
RO20.05.2020
RS20.05.2020
SI20.05.2020
SK20.05.2020
SM20.05.2020
TR20.05.2020
BG20.08.2020
GR21.08.2020
IS20.09.2020
PT21.09.2020
LU25.11.2020
[2022/32]
Former [2022/27]HU25.11.2016
AL20.05.2020
AT20.05.2020
CY20.05.2020
CZ20.05.2020
EE20.05.2020
HR20.05.2020
LT20.05.2020
LV20.05.2020
MC20.05.2020
MT20.05.2020
PL20.05.2020
RO20.05.2020
RS20.05.2020
SI20.05.2020
SK20.05.2020
SM20.05.2020
TR20.05.2020
BG20.08.2020
GR21.08.2020
IS20.09.2020
PT21.09.2020
LU25.11.2020
Former [2021/33]AL20.05.2020
AT20.05.2020
CZ20.05.2020
EE20.05.2020
HR20.05.2020
LT20.05.2020
LV20.05.2020
MC20.05.2020
PL20.05.2020
RO20.05.2020
RS20.05.2020
SI20.05.2020
SK20.05.2020
SM20.05.2020
BG20.08.2020
GR21.08.2020
IS20.09.2020
PT21.09.2020
LU25.11.2020
Former [2021/31]AL20.05.2020
AT20.05.2020
CZ20.05.2020
EE20.05.2020
HR20.05.2020
LT20.05.2020
LV20.05.2020
MC20.05.2020
PL20.05.2020
RO20.05.2020
RS20.05.2020
SI20.05.2020
SK20.05.2020
SM20.05.2020
BG20.08.2020
GR21.08.2020
IS20.09.2020
PT21.09.2020
Former [2021/24]AL20.05.2020
AT20.05.2020
CZ20.05.2020
EE20.05.2020
HR20.05.2020
LT20.05.2020
LV20.05.2020
PL20.05.2020
RO20.05.2020
RS20.05.2020
SI20.05.2020
SK20.05.2020
SM20.05.2020
BG20.08.2020
GR21.08.2020
IS20.09.2020
PT21.09.2020
Former [2021/10]AL20.05.2020
AT20.05.2020
CZ20.05.2020
EE20.05.2020
HR20.05.2020
LT20.05.2020
LV20.05.2020
PL20.05.2020
RO20.05.2020
RS20.05.2020
SK20.05.2020
SM20.05.2020
BG20.08.2020
GR21.08.2020
IS20.09.2020
PT21.09.2020
Former [2021/09]AL20.05.2020
AT20.05.2020
CZ20.05.2020
EE20.05.2020
HR20.05.2020
LT20.05.2020
LV20.05.2020
RO20.05.2020
RS20.05.2020
SM20.05.2020
BG20.08.2020
GR21.08.2020
IS20.09.2020
PT21.09.2020
Former [2021/04]AL20.05.2020
HR20.05.2020
LT20.05.2020
LV20.05.2020
RS20.05.2020
BG20.08.2020
GR21.08.2020
IS20.09.2020
PT21.09.2020
Former [2021/01]HR20.05.2020
LT20.05.2020
LV20.05.2020
RS20.05.2020
BG20.08.2020
GR21.08.2020
IS20.09.2020
PT21.09.2020
Former [2020/51]HR20.05.2020
LT20.05.2020
LV20.05.2020
RS20.05.2020
GR21.08.2020
IS20.09.2020
PT21.09.2020
Former [2020/50]HR20.05.2020
LT20.05.2020
LV20.05.2020
GR21.08.2020
IS20.09.2020
PT21.09.2020
Former [2020/49]LT20.05.2020
IS20.09.2020
PT21.09.2020
Former [2020/47]LT20.05.2020
IS20.09.2020
Former [2020/46]IS20.09.2020
Cited inInternational search[A]WO2015101957  (RHIZEN PHARMACEUTICALS SA [CH]) [A] 1-15 * whole document specially claim 1 and examples *;
 [AP]WO2015181539  (ASTRAZENECA AB [SE], et al) [AP] 1-15* Whole document, specially claim 1 *
by applicant   - CURI ET AL., FRONT. BIOSC., (2007), vol. 12, pages 344 - 57
    - DEBARDINIS; CHENG, ONCOGENE, vol. 2009, pages 313 - 324
    - KOPPENOL ET AL., NATURE REVIEWS, (2011), vol. 11, pages 325 - 337
    - HENSLEY ET AL., J. CLIN. INVEST., (2013), vol. 123, pages 3678 - 3684
    - DANG, CANCER RES., (2010), vol. 70, pages 859 - 863
    - ELGADI ET AL., PHYSIOL. GENOMICS, (1999), vol. 1, pages 51 - 62
    - CASSAGO ET AL., PROC. NATL. ACAD. SCI., (2012), vol. 109, pages 1092 - 1097
    - WANG ET AL., CANCER CELL, (2010), vol. 18, pages 207 - 219
    - VAN DER HEUVAL ET AL., CANCER BIO. THER., (2012), vol. 13, pages 1185 - 1194
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.